Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India

Clinical and Vaccine Immunology

Volumn 13, Issue 6, 2006, Pages 661-664

  Shivananda, ^a   Somani, Virbhadra ^a   Srikanth, B S ^a   Mohan, M ^a   Kulkarni, P S ^b  

^a INDIRA GANDHI INSTITUTE OF CHILD HEALTH   (India)

^b Serum Institute of India Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; GENEVAC B; HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIPHTHERIA; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNOGENICITY; INDIA; INFANT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; NEWBORN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SKIN INDURATION; TETANUS; VACCINATION REACTION;

DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INDIA; INFANT; MALE; STATISTICS, NONPARAMETRIC; VACCINES, SYNTHETIC;

EID: 33745828133     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00087-06     Document Type: Article

References (15)

1. Anonymous. 2006. MIMS India monthly index of medical specialties, vol. 26, p. 228-229. A. E. Morgan Publications (India) Private Ltd., New Delhi, India.
2. Gellissen, G., and C. P. Hollenberg. 1997. Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis-a review. Gene 190:87-97.
3. Gellissen, G., Z. A. Janowicz, U. Weydemann, K. Melber, A. W. Strasser, and C. P. Hollenberg. 1992. High-level expression of foreign genes in Hansenula polymorpha. Biotechnol. Adv. 10:179-189.
4. Goldfarb, J., J. Baley, S. V. Medendorp, D. Seto, H. Garcia, P. Toy, B. Watson, M. W. Gooch III, and D. Krause. 1994. Comparative study of immunogenicity and safety of two dosing schedules of recombinant DNA vaccine in neonates. Pediatr. Infect. Dis. J. 13:18-22.
5. Goldfarb, J., S. V. Medendorp, H. Garcia, K. Nagamori, H. Rathfon, and D. Krause. 1996. Comparison study of the immunogenicity and safety of 5- and 10-mg dosages of a recombinant hepatitis B vaccine in healthy infants. Pediatr. Infect. Dis. J. 15:764-767.
6. Goldfarb, J., S. V. Medendorp, K. Nagamori, C. Buscarino, and D. Krause. 1996. Comparison study of the immunogenicity and safety of 5 microgram and 10 microgram dosages of recombinant hepatitis B vaccine in healthy children. Pediatr. Infect. Dis. J. 15:768-771.
7. Greenberg, D. P., C. M. Vadheim, V. K. Wong, S. M. Marcy, S. Partridge, T. Greene, C. Y. Chiu, H. S. Margolis, and J. I. Ward. 1996. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age. Pediatr. Infect. Dis. J. 15:590-596.
8. Kakrani, A. L., R. Bharadwaj, A. Karmarkar, S. Joshi, S. Yadav, S. Bhardwaj, P. Kulkarni, and S. Kulkarni. 2003. Immune responses induced by two dose strengths of a yeast-derived recombinant hepatitis B vaccine in adolescents. Indian J. Gastroenterol. 22:71-72.
9. Kane, M. A., and J. Clements. 1993. Hepatitis B, p. 321-330. In D. T. Jamison, W. H. Mosley, A. R. Meashan, and J. Bobadilla (ed.), Disease control priorities in developing countries. Oxford University Press, New York, N. Y.
10. Keyserling, H. L., D. J. West, T. M. Hesley, C. Bosley, B. L. Wiens, and G. B. Calandra. 1994. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four and twelve or fifteen months of age. J. Pediatr. 125:67-69.
11. Park, K. 1997. Textbook of prevention and social medicine, 15th edition, p 159. M/S Banarsidas Bhanot Publishers, Jabalpur, India.
12. Thayagrajan, S. P., S. Jayaram, and B. Mohanvalli. 1996. Prevalence of HBV in general population of India, p. 5-16. In S. K. Sarin and A. K. Singhal (ed.), Hepatitis B in India: problems and prevention. CBS Publishers and Distributors, New Delhi, India.
13. Vijayakumar, V., R. Hari, R. Parthiban, J. Mehta, and S. P. Thyagarajan. 2004. Evaluation of immunogenicity and safety of Genevac B: a new recombinant hepatitis B vaccine in comparison with Engerix B and Shanvac B in healthy adults. Ind. J. Med. Microbiol. 22:34-38.
14. Vijayakumar, V., M. Shraddha, N. Subhadra, S. Saravanan, T. Sundararajan, and S. P. Thyagarajan. 2004. Immunogenicity and safety of 10 mg and 20 mg doses of Genevac-B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J. Gastroenterol. 23:34-35.
15. World Health Organization. 1992. WHO, 45th World Health Assembly, expanded programme on immunization and vaccine quality-progress report by the Director General, A45/8. World Health Organization, Geneva, Switzerland.